LOUIE ROSS: Open Payments
NPI 1801933031 · RICHLAND, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$565 in 16 payments from 9 companies in 2025. Trend: 2023 $933 · 2024 $636 · 2025 $565
Food & beverage: $565
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $151 |
| Kowa Pharmaceuticals America, Inc. | 1 | $105 |
| ABBVIE INC. | 4 | $93 |
| Novo Nordisk Inc | 2 | $85 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| Amgen Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14 |
Products named: CAPLYTA, ZORYVE, Ozempic, UBRELVY, XIFAXAN, AIRSUPRA, SYNTHROID, OTEZLA.
Industry payments across MS — which companies pay providers there.
